John Paul Roberts, MD
Obstetrics & Gynecology · Plano, TXNPI 1629076336
Payments from drug & device makers
Across 594 payments — averaging $8173.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3.1M
- GSK$1.8M
- Sanofi Pasteur Inc.$33K
- Merck$8K
- Mimedx Group, Inc.$6K
- AbbVie$370
- plus $2K from 34 others
Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
What the payments were for
- Consulting fees$6,20062%
- Travel & lodging$7497%
- Food & beverage$3,06631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 168 | $3,055,287 |
| GSK | 286 | $1,751,159 |
| Sanofi Pasteur Inc. | 13 | $32,531 |
| Merck | 2 | $7,500 |
| Mimedx Group, Inc. | 20 | $6,200 |
| AbbVie | 25 | $370 |
| Hologic Sales And Service, LLC | 5 | $189 |
| Mayne Pharma Commercial LLC | 8 | $152 |
| Amgen | 1 | $130 |
| Aspira Women's Health Inc | 2 | $125 |
| Bayer | 5 | $100 |
| Myovant Sciences Inc. | 3 | $68 |
| Avion Pharmaceuticals | 5 | $66 |
| Sage Therapeutics, LLC | 3 | $63 |
| Exeltis, USA Inc. | 4 | $62 |
| Innovation Technologies Inc | 2 | $58 |
| Modernatx, Inc. | 1 | $51 |
| Millicent US Inc | 3 | $50 |
| Daiichi Sankyo Inc. | 3 | $46 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Meditrina | 3 | $44 |
| Dexcom, Inc. | 2 | $43 |
| Minerva Surgical, Inc | 3 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $41 |
| Channel Medsystems, Inc. | 1 | $36 |
| Medtronic | 1 | $32 |
| Gen-probe, Inc. | 1 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Avanos Medical | 1 | $25 |
| Vertical Pharmaceuticals, LLC | 1 | $24 |
| Organon | 2 | $22 |
| Therapeuticsmd, Inc. | 2 | $22 |
| Agile Therapeutics, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Coopersurgical, Inc. | 1 | $20 |
| Mycovia Pharmaceuticals, Inc. | 1 | $18 |
| BD | 1 | $17 |
| Duchesnay USA Incorporated | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Unified Women's Healthcare, LP | 5 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOVINE COLLAGEN$400
How this compares
$4,854,771 in reported general payments places this provider in the 95th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 14 | $682 |
| ProgesteroneProgesterone, Micronized | 20 | $460 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Plano
- Phyllis GeePlano$432K
- Elizabeth CoronadoPlano$155K
- Amir JazaeriHouston$19.5M
- Shannon WestinHouston$17.3M
- Monica LopezFort Worth$8.1M
- Cynthia RobbinsFort Worth$7.8M
- Stephen StamatisWeatherford$4.5M
- Parke HedgesSan Antonio$4.2M
- Mary MartinBeaumont$2.8M
- Mark JacobsHouston$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.